Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Newly formed Mirrx gets undisclosed amount in seed round

Executive Summary

Concurrent with its spin off from Stealth Biotech, antisense company Mirrx Therapeutics has raised an undisclosed amount in its seed financing from Seed Capital, Inventure Capital, and Vecata Invest.
Deal Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Spin-Off
    • Private Placement

Related Companies

Advertisement
UsernamePublicRestriction

Register